ATRA
Atara Biotherapeutics, Inc.
$9.76
-0.19 (-1.86%)
At close · Jul 10
Market Cap
$87.94M
Shares
9,010,172
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.76
Open$10.06
Day$9.36–10.06
52W$3.92–19.15
Avg vol 30d85K
Short int362K · 4.0% float · 4.0d
Short vol77%
Last earningsNov 1, 2023
DataJan 2020–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+3%
above
RSI (14)
46
neutral
MACD trend
Negative
52-week position
38%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+111%
trailing
YTD return
−46%
this year
Relative strength
+102%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Flat
1 of 34 funds reported for Jun 30 · net 0 sh shares
Insider flow
Accumulating
Net +$1.5M over 90 days · 75% sells
Short interest
Falling
4.01% of float · ▼ -26.6% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — mid 2-yr range
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
−6%
Y/Y
EPS growth
+123%
Y/Y
Free cash flow
$-50.9M
Balance sheet
$8.5M
net cash
Quant / Vol
risk profile
Volatility
145%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
8.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+3%
Bullish
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
38%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Flat
1 of 34 funds reported for Jun 30 · net 0 sh shares
Insider flow
Accumulating
Net +$1.5M over 90 days · 75% sells
Short interest
Falling
4.01% of float · ▼ -26.6% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $4
Now $10 · 38%
52-wk high $19
vs 200-day avg -1%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATRA
this stock
Atara Biotherapeutics, Inc.
|
$87.94M | -46.0% | -6.3% | — | 4.0% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATRA | -16.2% | -1.0% | +111.3% | -15.0% | -46.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -17.6% | -5.1% | +102.2% | -16.1% | -56.8% |